These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 18287589

  • 1. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
    Hennekens CH, Borzak S.
    J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):41-50. PubMed ID: 18287589
    [Abstract] [Full Text] [Related]

  • 2. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP, Gertler R, Fricker R.
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [Abstract] [Full Text] [Related]

  • 9. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O, Solomon SD.
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [Abstract] [Full Text] [Related]

  • 10. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
    van Staa TP, Rietbrock S, Setakis E, Leufkens HG.
    J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
    Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of cyclooxygenase-2 inhibitors.
    Brophy JM.
    Curr Opin Gastroenterol; 2007 Nov; 23(6):617-24. PubMed ID: 17906437
    [Abstract] [Full Text] [Related]

  • 14. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.
    Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM.
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):641-52. PubMed ID: 16392153
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
    Maillard M, Burnier M.
    Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.